
  
    
      
        Introduction_NNP
        Between_IN 1990_CD and_CC 1995_CD ,_, the_DT organ_NN transplant_NN waiting_VBG list_NN
        in_IN the_DT US_NNP more_RBR than_IN doubled_VBD to_TO over_IN 43_CD ,_, 000_CD patients_NNS [_NN 1_CD ]_NN ._.
        The_DT donor_NN pool_NN necessary_JJ to_TO meet_VB current_JJ US_NNP transplantation_NN
        needs_VBZ has_VBZ been_VBN projected_VBN to_TO between_IN 10_CD ,_, 000_CD and_CC 15_CD ,_, 000_CD per_IN
        year_NN [_NN 2_CD ,_, 3_CD ]_NN ._. The_DT major_JJ obstacle_NN to_TO organ_NN transplantation_NN
        is_VBZ the_DT limited_JJ organ_NN supply_NN [_NN 2_CD ,_, 4_CD ]_NN ._. Consequently_RB ,_, in_IN the_DT
        early_JJ 1990_CD s_VBZ ,_, nearly_RB 2000_CD patients_NNS died_VBD in_IN the_DT US_NNP each_DT year_NN
        while_IN on_IN organ_NN transplantation_NN waiting_VBG lists_NNS [_NN 5_CD ]_NN ;_:
        currently_RB ,_, this_DT number_NN may_MD be_VB as_RB high_JJ as_IN 3500_CD [_NN 1_CD ]_NN ._. It_PRP has_VBZ
        been_VBN estimated_VBN that_IN between_IN 12_CD ,_, 500_CD and_CC 27_CD ,_, 000_CD potential_JJ
        organ_NN donors_NNS die_VBP each_DT year_NN in_IN the_DT US_NNP [_NN 2_CD ,_, 6_CD ]_NN ._. Despite_IN what_WP
        seems_VBZ to_TO be_VB an_DT adequate_JJ donor_NN pool_NN ,_, only_RB 15_CD to_TO 20_CD 
        %_NN of_IN potential_JJ donors_NNS become_VBP actual_JJ
        donors_NNS ,_, approximately_RB 98_CD 
        %_NN of_IN whom_WP originate_VB from_IN intensive_JJ
        care_NN units_NNS (_( ICUs_NNP )_) [_NN 7_CD ,_, 8_CD ]_NN ._. Because_IN many_JJ factors_NNS contribute_VBP
        to_TO the_DT shortage_NN of_IN organs_NNS ,_, early_JJ donor_NN recognition_NN ,_, rapid_JJ
        and_CC accurate_JJ declaration_NN of_IN brain_NN death_NN ,_, physiological_JJ
        maintenance_NN of_IN potential_JJ organ_NN donors_NNS ,_, and_CC coordination_NN
        with_IN the_DT local_JJ organ_NN procurement_NN organization_NN (_( OPO_NNP )_) are_VBP all_DT
        important_JJ aspects_NNS of_IN organ_NN donor_NN management_NN [_NN 9_CD ]_NN ._.
        Once_RB a_DT potential_JJ donor_NN has_VBZ been_VBN identified_VBN ,_, brain_NN death_NN
        must_MD be_VB legally_RB determined_VBN [_NN 10_CD ,_, 11_CD ]_NN ._. The_DT multiple_JJ
        physiological_JJ derangements_NNS which_WDT the_DT potential_JJ organ_NN donor_NN
        manifests_NNS require_VBP aggressive_JJ ,_, labor_NN intensive_JJ management_NN in_IN
        order_NN to_TO maintain_VB organ_NN function_NN until_IN legal_JJ brain_NN death_NN is_VBZ
        declared_VBN and_CC procurement_NN can_MD be_VB undertaken_VBN [_NN 12_CD ]_NN ._. One_CD
        recent_JJ review_NN suggests_VBZ that_IN the_DT medical_JJ failures_NNS occurring_VBG
        prior_RB to_TO organ_NN procurement_NN in_IN brain_NN dead_JJ patients_NNS may_MD be_VB
        largely_RB preventable_JJ by_IN the_DT use_NN of_IN invasive_JJ hemodynamic_JJ
        monitoring_NN ,_, aggressive_JJ rewarming_VBG and_CC liberal_JJ transfusion_NN
        therapy_NN [_NN 13_CD ]_NN ._. The_DT level_NN of_IN care_NN necessary_JJ to_TO sustain_VB
        potential_JJ organ_NN donors_NNS until_IN legal_JJ brain_NN death_NN is_VBZ declared_VBN
        is_VBZ expensive_JJ [_NN 14_CD ]_NN ._. These_DT charges_NNS ,_, accrued_VBN before_IN the_DT OPO_NNP
        assumes_VBZ financial_JJ responsibility_NN ,_, may_MD be_VB unknowingly_RB
        referred_VBN to_TO donor_NN families_NNS ,_, essentially_RB penalizing_VBG them_PRP for_IN
        the_DT altruistic_JJ act_NN of_IN organ_NN donation_NN ._.
        This_DT review_NN was_VBD performed_VBN in_IN order_NN to_TO measure_VB the_DT impact_NN
        of_IN altering_VBG the_DT use_NN of_IN the_DT brain_NN death_NN determination_NN
        protocol_NN at_IN the_DT University_NNP of_IN Pennsylvania_NNP Medical_NNP Center_NNP ,_,
        in_IN an_DT attempt_NN to_TO decrease_VB the_DT time_NN between_IN the_DT first_JJ
        examination_NN consistent_JJ with_IN brain_NN death_NN and_CC actual_JJ legal_JJ
        determination_NN of_IN brain_NN death_NN (_( brain_NN death_NN stay_NN )_) ._. The_DT impact_NN
        on_IN the_DT organ_NN procurement_NN process_NN ,_, including_VBG hospital_NN
        charges_NNS ,_, length_NN of_IN brain_NN death_NN stay_NN ,_, and_CC number_NN of_IN organs_NNS
        procured_JJ per_IN patient_NN was_VBD studied_VBN ._.
      
      
        Materials_NNS and_CC methods_NNS
        With_IN cooperation_NN from_IN the_DT Delaware_NNP Valley_NNP Transplant_NNP
        Program_NNP ,_, the_DT local_JJ OPO_NNP ,_, traumatically_RB injured_VBN organ_NN and_CC
        tissue_NN donors_NNS cared_VBD for_IN between_IN 1_CD July_NNP 1991_CD and_CC 31_CD December_NNP
        1996_CD at_IN the_DT University_NNP of_IN Pennsylvania_NNP Medical_NNP Center_NNP (_( an_DT
        urban_JJ Level_NNP 1_CD trauma_NN center_NN )_) were_VBD identified_VBN ._. Two_CD groups_NNS of_IN
        trauma_NN patients_NNS were_VBD studied_VBN :_: group_NN I_PRP consisted_VBD of_IN 31_CD
        patients_NNS evaluated_VBN between_IN 1_CD July_NNP 1991_CD and_CC 30_CD June_NNP 1995_CD ,_,
        and_CC group_NN II_NNP consisted_VBD of_IN seven_CD patients_NNS evaluated_VBN between_IN
        1_CD January_NNP and_CC 31_CD December_NNP 1996_CD ._. The_DT OPO_NNP and_CC hospital_NN
        medical_JJ records_NNS for_IN these_DT patients_NNS were_VBD reviewed_VBN ._.
        Demographic_NNP information_NN ,_, including_VBG age_NN ,_, sex_NN and_CC mechanism_NN
        of_IN injury_NN was_VBD abstracted_JJ ._. In_IN addition_NN ,_, the_DT timing_NN of_IN
        specific_JJ diagnostic_JJ studies_NNS and_CC therapies_NNS such_JJ as_IN
        laboratory_NN tests_NNS ,_, radiographs_NNS ,_, medications_NNS ,_, and_CC
        transfusions_NNS were_VBD recorded_VBN for_IN concurrent_JJ financial_JJ
        analysis_NN with_IN charges_NNS obtained_VBN from_IN itemized_JJ hospital_NN
        billing_NN sheets_NNS ._.
        The_DT presence_NN or_CC absence_NN of_IN specific_JJ major_JJ medical_JJ
        complications_NNS during_IN the_DT hospital_NN stay_NN was_VBD determined_VBN by_IN
        medical_JJ record_NN review_NN ._. Clinical_NNP complications_NNS ,_, based_VBN on_IN a_DT
        chart_NN review_NN of_IN specific_JJ interventions_NNS by_IN clinicians_NNS caring_VBG
        for_IN these_DT patients_NNS rather_RB than_IN on_IN strict_JJ predefined_JJ
        criteria_NNS ,_, were_VBD defined_VBN as_IN :_:
        1_LS ._. cardiovascular_JJ instability_NN -_: blood_NN pressure_NN support_NN
        with_IN a_DT vasopressor_NN ;_:
        2_LS ._. cardiovascular_JJ instability_NN -_: invasive_JJ hemodynamic_JJ
        monitoring_NN with_IN a_DT Swan_NN Ganz_NNP catheter_NN ;_:
        3_LS ._. anemia_NN -_: transfusion_NN of_IN packed_VBN red_JJ blood_NN cells_NNS
        (_( PRBC_NNP )_) ;_:
        4_LS ._. coagulopathy_NN -_: transfusion_NN of_IN fresh_JJ frozen_VBN plasma_NN
        (_( FFP_NNP )_) or_CC platelets_NNS (_( PLTS_NNP )_) ,_, and_CC
        5_LS ._. diabetes_NN insipidus_JJ (_( DI_NNP )_) -_: treatment_NN with_IN vasopressin_NN
        infusion_NN ._.
        Because_IN of_IN their_PRP$ depressed_VBN neurological_JJ status_NN ,_, all_DT
        patients_NNS were_VBD maintained_VBN on_IN mechanical_JJ ventilation_NN ._.
        Therefore_RB ,_, pulmonary_JJ complications_NNS were_VBD not_RB thought_VBN to_TO add_VB
        differently_RB to_TO charges_NNS between_IN groups_NNS ,_, and_CC the_DT incidence_NN of_IN
        respiratory_JJ insufficiency_NN was_VBD not_RB calculated_VBN ._.
        At_IN the_DT University_NNP of_IN Pennsylvania_NNP ,_, brain_NN death_NN is_VBZ
        basically_RB defined_VBN by_IN :_:
        1_LS ._. two_CD neurological_JJ examinations_NNS demonstrating_VBG lack_NN of_IN
        cortical_JJ and_CC brainstem_NN function_NN ,_, performed_VBD 12_CD h_NN apart_RB ;_:
        2_LS ._. two_CD neurological_JJ examinations_NNS performed_VBD 6_CD h_NN apart_RB
        along_IN with_IN a_DT confirmatory_NN electroencephalogram_NN documenting_VBG
        lack_NN of_IN cortical_JJ function_NN ,_, or_CC
        3_LS ._. a_DT single_JJ brain_NN death_NN examination_NN demonstrating_VBG a_DT lack_NN
        of_IN cortical_JJ and_CC brainstem_NN function_NN in_IN conjunction_NN with_IN a_DT
        confirmatory_NN nuclear_JJ medicine_NN brain_NN flow_NN scan_VB demonstrating_VBG
        absence_NN of_IN cerebral_JJ blood_NN flow_NN ._.
        Until_IN January_NNP 1996_CD ,_, brain_NN death_NN was_VBD typically_RB determined_VBN
        using_VBG one_CD of_IN the_DT first_JJ two_CD methods_NNS described_VBD above_IN ._. The_DT
        third_JJ option_NN was_VBD reserved_VBN for_IN patients_NNS with_IN equivocal_NN
        examinations_NNS due_JJ to_TO confounding_VBG factors_NNS (_( pentobarbital_NN ,_,
        etc_FW )_) ._. In_IN order_NN to_TO speed_VB the_DT determination_NN of_IN brain_NN death_NN
        and_CC potentially_RB reduce_VB costly_JJ ICU_NNP stays_VBZ ,_, beginning_VBG in_IN
        January_NNP 1996_CD the_DT brain_NN flow_NN scan_VB became_VBD the_DT primary_JJ method_NN
        of_IN confirming_VBG brain_NN death_NN in_IN our_PRP$ trauma_NN patient_NN
        population_NN ._.
        The_DT nuclear_JJ medicine_NN brain_NN flow_NN scan_VB is_VBZ performed_VBN by_IN
        intravenous_JJ injection_NN of_IN 20_CD -_: 25_CD mCi_NN of_IN either_DT 99_CD mTc_NN labeled_VBD
        HMPAO_NNP or_CC ECD_NNP followed_VBD 25_CD -_: 30_CD min_NN later_RB by_IN conventional_JJ
        lateral_NN planar_NN imaging_NN of_IN the_DT patient_NN 's_POS head_NN using_VBG a_DT
        scintillation_NN camera_NN interfaced_JJ to_TO a_DT digital_JJ computer_NN ._.
        These_DT scans_NNS are_VBP performed_VBN in_IN the_DT radiology_NN department_NN
        without_IN moving_VBG the_DT patient_NN from_IN the_DT bed_NN to_TO a_DT scanning_VBG
        table_NN ,_, thus_RB facilitating_VBG timely_JJ acquisition_NN of_IN the_DT
        necessary_JJ images_NNS ._. The_DT images_NNS are_VBP then_RB interpreted_VBN by_IN
        on-screen_JJ visual_JJ inspection_NN ,_, allowing_VBG optimal_NN evaluation_NN of_IN
        the_DT degree_NN of_IN blood_NN flow_NN to_TO the_DT brain_NN ._. Under_IN normal_JJ
        circumstances_NNS ,_, a_DT substantial_JJ uptake_NN of_IN the_DT aforementioned_JJ
        radio_NN tracers_NNS is_VBZ noted_VBN in_IN the_DT brain_NN and_CC cerebellum_NN (_( Fig_NNP 1_LS )_) ._.
        In_IN patients_NNS with_IN brain_NN death_NN ,_, no_DT detectable_JJ uptake_NN is_VBZ
        noted_VBN ._. In_IN fact_NN ,_, uptake_NN in_IN the_DT scalp_NN and_CC skull_NN ,_, which_WDT is_VBZ not_RB
        typically_RB seen_VBN in_IN images_NNS from_IN normal_JJ patients_NNS ,_, appears_VBZ
        quite_RB prominent_JJ in_IN those_DT with_IN brain_NN death_NN ,_, allowing_VBG
        definition_NN of_IN the_DT contours_NNS of_IN the_DT head_NN in_IN such_JJ subjects_NNS
        (_( Fig_NNP 2_LS )_) ._.
        For_IN each_DT patient_NN in_IN group_NN I_PRP ,_, the_DT specific_JJ timing_NN of_IN the_DT
        first_JJ and_CC second_JJ brain_NN death_NN examinations_NNS was_VBD recorded_VBN ._.
        Likewise_RB ,_, for_IN each_DT patient_NN in_IN group_NN II_NNP ,_, the_DT specific_JJ timing_NN
        of_IN the_DT brain_NN death_NN examination_NN and_CC nuclear_JJ medicine_NN scan_VB
        result_NN ,_, coinciding_VBG with_IN official_JJ declaration_NN of_IN death_NN ,_, was_VBD
        recorded_VBN ._.
        The_DT brain_NN death_NN stay_NN was_VBD determined_VBN for_IN each_DT patient_NN ._.
        Because_IN OPOs_NNP assume_VB patient_NN management_NN responsibility_NN upon_IN
        declaration_NN of_IN death_NN ,_, individual_JJ clinicians_NNS have_VBP no_DT
        influence_NN over_IN events_NNS after_IN this_DT time_NN ._. Therefore_RB ,_, no_DT
        attempt_NN was_VBD made_VBN to_TO quantify_VB the_DT period_NN between_IN declaration_NN
        of_IN death_NN and_CC organ_NN procurement_NN ,_, or_CC to_TO identify_VB
        complications_NNS developed_VBN during_IN this_DT time_NN ._. Itemized_NNP
        financial_JJ records_NNS of_IN all_DT patients_NNS were_VBD reviewed_VBN
        concurrently_RB with_IN their_PRP$ medical_JJ records_NNS ._. The_DT timing_NN of_IN
        diagnostic_JJ and_CC therapeutic_JJ maneuvers_NNS ,_, including_VBG the_DT nuclear_JJ
        medicine_NN scan_VB ,_, was_VBD cross-referenced_JJ with_IN the_DT patient_NN 's_POS
        itemized_JJ hospital_NN bill_NN ._. Individual_JJ item_NN charges_NNS were_VBD then_RB
        credited_VBN to_TO the_DT specific_JJ brain_NN death_NN stay_NN period_NN as_IN
        described_VBN above_IN ._. Of_IN note_NN ,_, charges_NNS associated_VBN with_IN
        diagnostic_JJ studies_NNS which_WDT were_VBD part_NN of_IN the_DT donor_NN evaluation_NN
        process_NN (_( eg_NN echocardiography_NN ,_, hepatitis_NN serology_NN )_) and_CC were_VBD
        specifically_RB ordered_VBN by_IN ,_, and_CC therefore_RB billed_VBN to_TO ,_, the_DT OPO_NNP
        during_IN and_CC after_IN the_DT brain_NN death_NN stay_NN were_VBD not_RB credited_VBN
        against_IN the_DT patient_NN as_IN brain_NN death_NN stay_NN charges_NNS ._. All_DT data_NNS
        are_VBP displayed_VBN as_IN mean_NN ±_NN standard_JJ error_NN of_IN the_DT mean_NN ._.
        Statistical_NNP analysis_NN was_VBD performed_VBN using_VBG the_DT Mann-_NNP Whitney_NNP U_NNP
        test_NN ._.
      
      
        Results_NNS
        Thirty-one_NNP organ_NN and_CC /_NN or_CC tissue_NN donors_NNS were_VBD identified_VBN in_IN
        group_NN I_PRP and_CC seven_CD in_IN group_NN II_NNP ._. Demographic_NNP data_NNS are_VBP
        displayed_VBN in_IN Table_NNP 1_CD ._. Reflecting_VBG the_DT urban_JJ trauma_NN
        population_NN ,_, donors_NNS were_VBD most_RBS commonly_RB young_JJ ,_,
        African-_NNP American_JJ males_NNS who_WP had_VBD sustained_VBN a_DT gunshot_NN wound_VBD to_TO
        the_DT head_NN ._. In_IN group_NN I_PRP ,_, 28_CD patients_NNS were_VBD declared_VBN brain_NN dead_JJ
        and_CC went_VBD on_IN to_TO donate_VB 4_CD ._. 1_CD ±_NN 0_CD ._. 2_CD organs_NNS /_NN donor_NN ._. Three_CD
        patients_NNS died_VBD in_IN the_DT ICU_NNP prior_RB to_TO brain_NN death_NN determination_NN
        and_CC became_VBD tissue_NN donors_NNS ._. These_DT three_CD patients_NNS did_VBD not_RB
        reach_VB their_PRP$ second_JJ brain_NN death_NN examination_NN and_CC were_VBD
        therefore_RB excluded_VBN from_IN further_JJ consideration_NN in_IN the_DT brain_NN
        death_NN stay_NN group_NN ._. In_IN group_NN II_NNP ,_, all_DT seven_CD patients_NNS were_VBD
        declared_VBN brain_NN dead_JJ using_VBG the_DT modified_VBN protocol_NN and_CC went_VBD on_IN
        to_TO donate_VB 4_CD ._. 4_CD ±_NN 1_CD ._. 4_CD organs_NNS /_NN donor_NN ._.
        Major_NNP medical_JJ complications_NNS during_IN the_DT hospital_NN course_NN
        were_VBD reviewed_VBN ._. Every_DT study_NN patient_NN developed_VBD one_CD or_CC more_RBR
        major_JJ complication_NN ._. Hypotension_NNP requiring_VBG intervention_NN with_IN
        one_CD or_CC more_JJR vasopressor_NN agents_NNS was_VBD the_DT most_RBS common_NN of_IN these_DT
        complications_NNS ._. The_DT hematologic_JJ complications_NNS of_IN anemia_NN and_CC
        coagulopathy_NN requiring_VBG blood_NN component_NN therapy_NN with_IN PRBCs_NNP ,_,
        FFP_NNP or_CC PLTS_NNP were_VBD also_RB frequently_RB noted_VBD (_( Table_NNP 2_LS )_) ._. The_DT mean_JJ
        number_NN of_IN complications_NNS per_IN patient_NN was_VBD 3_CD ._. 2_CD ±_NN 0_CD ._. 2_CD in_IN group_NN
        I_PRP ,_, and_CC 4_CD ._. 0_CD ±_NN 1_CD ._. 3_CD in_IN group_NN II_NNP ._. The_DT difference_NN was_VBD not_RB
        statistically_RB significant_JJ (_( Table_NNP 3_LS )_) ._.
        The_DT mean_JJ brain_NN death_NN stay_NN for_IN each_DT group_NN was_VBD calculated_VBN ,_,
        and_CC was_VBD 12_CD ._. 0_CD ±_NN 1_CD ._. 0_CD h_NN for_IN group_NN I_PRP ,_, and_CC 3_CD ._. 5_CD ±_NN 1_CD ._. 8_CD h_NN for_IN group_NN
        II_NNP ._. The_DT mean_JJ brain_NN death_NN stay_NN for_IN group_NN II_NNP was_VBD
        significantly_RB shorter_JJR (_( 
        P_NN <_NN 0_CD ._. 01_CD )_) (_( Table_NNP 3_LS )_) ._.
        Itemized_NNP financial_JJ records_NNS of_IN all_DT 35_CD study_NN patients_NNS were_VBD
        reviewed_VBN ._. Charges_NNS for_IN ICU_NNP stay_VB as_RB well_RB as_IN specific_JJ
        diagnostic_JJ studies_NNS and_CC therapeutic_JJ maneuvers_NNS were_VBD
        identified_VBN ._. These_DT charges_NNS were_VBD cross-referenced_JJ with_IN the_DT
        patients_NNS medical_JJ records_NNS and_CC individual_JJ charges_NNS were_VBD
        credited_VBN to_TO specific_JJ periods_NNS before_RB ,_, during_IN and_CC after_IN the_DT
        brain_NN death_NN stay_NN period_NN ._. Mean_VB charges_NNS accrued_VBN during_IN the_DT
        brain_NN death_NN stay_NN were_VBD $_$ 16_CD ,_, 645_CD ±_NN 1223_CD for_IN group_NN I_PRP and_CC $_$ 6125_CD
        ±_NN 1100_CD for_IN group_NN II_NNP ,_, which_WDT was_VBD significantly_RB less_JJR (_( 
        P_NN <_NN 0_CD ._. 01_CD )_) (_( Table_NNP 3_LS )_) ._.
      
      
        Discussion_NNP
        Throughout_IN the_DT world_NN ,_, the_DT shortage_NN of_IN donor_NN organs_NNS has_VBZ
        reached_VBN critical_JJ proportions_NNS ._. Despite_IN efforts_NNS to_TO increase_VB
        the_DT national_JJ supply_NN ,_, the_DT number_NN of_IN patients_NNS dying_VBG in_IN the_DT US_NNP
        while_IN awaiting_VBG solid_JJ organ_NN transplantation_NN has_VBZ risen_VBN from_IN
        six_CD per_IN day_NN at_IN the_DT start_NN of_IN the_DT study_NN period_NN ,_, to_TO 10_CD per_IN day_NN
        currently_RB [_NN 1_CD ,_, 5_CD ]_NN ._. Attempts_NNS to_TO increase_VB referrals_NNS to_TO OPOs_NNP
        by_IN enacting_VBG mandatory_JJ request_NN laws_NNS have_VBP had_VBN minimal_JJ impact_NN
        on_IN organ_NN donation_NN rates_NNS [_NN 15_CD ]_NN ._. Once_RB a_DT potential_JJ organ_NN donor_NN
        is_VBZ referred_VBN to_TO an_DT OPO_NNP ,_, the_DT failure_NN to_TO obtain_VB consent_NN from_IN
        the_DT next_JJ of_IN kin_NN remains_VBZ the_DT single_JJ largest_JJS cause_NN of_IN
        eligible_JJ organ_NN procurement_NN failure_NN ,_, with_IN more_JJR than_IN 40_CD 
        %_NN of_IN families_NNS refusing_VBG donation_NN [_NN 13_CD ,_,
        16_CD ,_, 17_CD ]_NN ._.
        Since_IN 1990_CD ,_, firearms_NNS have_VBP surpassed_VBN motor_NN vehicle_NN
        crashes_NNS as_IN the_DT single_JJ largest_JJS cause_NN of_IN lethal_JJ traumatic_JJ
        brain_NN injury_NN in_IN the_DT US_NNP [_NN 18_CD ]_NN ._. This_DT trend_NN is_VBZ consistent_JJ with_IN
        our_PRP$ findings_NNS (_( Table_NNP 1_LS )_) ._. Unfortunately_RB ,_, the_DT individuals_NNS most_RBS
        likely_JJ to_TO be_VB involved_VBN in_IN inter-personal_JJ firearm_NN violence_NN
        seem_VBP to_TO come_VB from_IN families_NNS less_RBR likely_JJ to_TO agree_VB to_TO organ_NN
        donation_NN when_WRB compared_VBN to_TO the_DT general_JJ population_NN [_NN 19_CD ,_, 20_CD ]_NN ._.
        Multiple_NNP efforts_NNS to_TO educate_VB the_DT population_NN at_IN large_JJ on_IN the_DT
        societal_NN benefits_NNS of_IN organ_NN donation_NN are_VBP underway_NN but_CC the_DT
        impetus_NN to_TO donate_VB remains_VBZ one_CD based_VBN largely_RB on_IN
        altruism_NN ._.
        From_IN initial_JJ hospitalization_NN until_IN organ_NN procurement_NN or_CC
        cessation_NN of_IN life_NN support_NN ,_, the_DT potential_JJ organ_NN donor_NN
        manifests_NNS daunting_JJ medical_JJ challenges_NNS due_JJ to_TO the_DT dramatic_JJ
        physiological_JJ changes_NNS that_WDT accompany_VB the_DT development_NN of_IN
        brain_NN death_NN ._. The_DT principle_NN goals_NNS of_IN medical_JJ management_NN of_IN
        the_DT organ_NN donor_NN include_VBP early_JJ recognition_NN and_CC treatment_NN of_IN
        hemodynamic_JJ instability_NN ,_, maintenance_NN of_IN systemic_JJ perfusion_NN
        pressure_NN to_TO maximize_VB post-transplantation_JJ allograft_NN
        function_NN ,_, and_CC the_DT prevention_NN and_CC treatment_NN of_IN other_JJ
        complications_NNS related_VBN to_TO brain_NN death_NN and_CC supportive_JJ care_NN ._.
        Ideally_RB ,_, medical_JJ management_NN of_IN the_DT potential_JJ multi-organ_JJ
        donor_NN begins_VBZ once_RB it_PRP seems_VBZ that_DT brain_NN death_NN is_VBZ inevitable_JJ
        and_CC that_IN the_DT likelihood_NN of_IN donation_NN by_IN the_DT family_NN is_VBZ high_JJ [_NN
        9_CD ]_NN ._.
        Major_NNP medical_JJ complications_NNS were_VBD universal_JJ in_IN this_DT study_NN
        population_NN ._. Every_DT patient_NN developed_VBN at_IN least_JJS one_CD
        complication_NN ._. Hypotension_NNP requiring_VBG treatment_NN with_IN
        vasopressors_NNS and_CC /_NN or_CC invasive_JJ hemodynamic_JJ monitoring_NN was_VBD the_DT
        most_RBS frequent_JJ complication_NN ._. Hematologic_NNP abnormalities_NNS
        requiring_VBG blood_NN component_NN transfusion_NN were_VBD also_RB seen_VBN in_IN
        over_IN 80_CD %_NN of_IN the_DT patients_NNS ._. Additional_JJ complications_NNS ,_, such_JJ as_IN
        DI_NNP were_VBD also_RB common_JJ (_( Table_NNP 2_LS )_) ._. These_DT results_NNS are_VBP consistent_JJ
        with_IN other_JJ studies_NNS which_WDT have_VBP reported_VBN similar_JJ complication_NN
        rates_NNS during_IN the_DT brain_NN death_NN stay_NN period_NN [_NN 21_CD ,_, 22_CD ,_, 23_CD ]_NN ._. Of_IN
        note_NN ;_: the_DT incidence_NN of_IN coagulopathy_NN reported_VBD in_IN our_PRP$ series_NN
        is_VBZ higher_JJR than_IN that_DT reported_VBD in_IN the_DT general_JJ organ_NN donor_NN
        population_NN [_NN 21_CD ,_, 23_CD ]_NN ._. This_DT is_VBZ most_RBS likely_RB explained_VBN by_IN the_DT
        nature_NN of_IN the_DT lethal_JJ brain_NN insult_NN in_IN our_PRP$ trauma_NN
        population_NN ._.
        Unfortunately_RB ,_, 17_CD -_: 25_CD %_NN of_IN potential_JJ organ_NN donors_NNS are_VBP lost_VBN
        due_JJ to_TO medical_JJ failure_NN [_NN 13_CD ,_, 16_CD ]_NN ._. Complications_NNP related_VBD to_TO
        prolonged_JJ supportive_JJ care_NN ,_, as_IN a_DT consequence_NN of_IN delays_NNS in_IN
        the_DT diagnosis_NN of_IN brain_NN death_NN ,_, reduce_VBP the_DT availability_NN and_CC
        suitability_NN of_IN potentially_RB transplantable_JJ organs_NNS [_NN 24_CD ,_, 25_CD ]_NN ._.
        One_CD recent_JJ review_NN suggests_VBZ that_IN the_DT medical_JJ failures_NNS
        occurring_VBG during_IN the_DT time_NN leading_VBG up_RP to_TO actual_JJ organ_NN
        procurement_NN in_IN brain_NN dead_JJ patients_NNS may_MD be_VB preventable_JJ with_IN
        early_JJ invasive_JJ hemodynamic_JJ monitoring_NN ,_, aggressive_JJ rewarming_VBG
        and_CC liberal_JJ transfusion_NN therapy_NN ,_, all_DT readily_RB available_JJ in_IN a_DT
        modern_JJ critical_JJ care_NN setting_VBG [_NN 13_CD ]_NN ._. This_DT aggressive_JJ
        management_NN ,_, which_WDT is_VBZ necessary_JJ to_TO maintain_VB organ_NN function_NN
        until_IN brain_NN death_NN is_VBZ declared_VBN and_CC procurement_NN can_MD be_VB
        undertaken_VBN ,_, is_VBZ extremely_RB labor_NN and_CC resource_NN intensive_JJ [_NN 13_CD ,_,
        16_CD ,_, 21_CD ,_, 22_CD ,_, 23_CD ,_, 26_CD ]_NN ._. As_IN a_DT result_NN ,_, significant_JJ costs_NNS are_VBP
        accrued_VBN and_CC charges_NNS generated_VBN while_IN awaiting_VBG the_DT
        declaration_NN of_IN brain_NN death_NN ._. A_DT rapid_JJ ,_, accurate_JJ diagnosis_NN of_IN
        brain_NN death_NN would_MD seem_VB to_TO facilitate_VB the_DT organ_NN procurement_NN
        process_NN and_CC may_MD well_RB decrease_VB its_PRP$ associated_VBN charges_NNS [_NN
        27_CD ]_NN ._.
        In_IN this_DT study_NN ,_, the_DT mean_JJ charge_NN for_IN total_JJ hospital_NN stay_NN
        included_VBD charges_NNS accrued_VBN during_IN initial_JJ evaluation_NN in_IN the_DT
        trauma_NN resuscitation_NN area_NN ,_, during_IN the_DT ICU_NNP stay_NN and_CC during_IN
        actual_JJ organ_NN procurement_NN ._. All_DT charges_NNS accrued_VBN after_IN the_DT
        patient_NN was_VBD declared_VBN legally_RB brain_NN dead_JJ ,_, and_CC charges_NNS for_IN
        diagnostic_JJ studies_NNS specifically_RB ordered_VBN by_IN the_DT OPO_NNP during_IN
        the_DT brain_NN death_NN stay_NN as_IN a_DT part_NN of_IN the_DT donor_NN evaluation_NN
        process_NN ,_, were_VBD the_DT responsibility_NN of_IN the_DT local_JJ OPO_NNP as_IN per_IN
        national_JJ standards_NNS (_( Hawthorne_NN RV_NN ,_, pers_NNS comm_NN )_) ._. Charges_NNS
        accrued_VBN before_IN the_DT legal_JJ determination_NN of_IN brain_NN death_NN were_VBD
        not_RB billed_VBN to_TO the_DT local_JJ OPO_NNP ._. In_IN this_DT study_NN these_DT included_VBD
        $_$ 16_CD ,_, 645_CD ±_NN 1223_CD in_IN patient_NN charges_NNS during_IN the_DT brain_NN death_NN
        stay_NN in_IN group_NN I_PRP and_CC $_$ 6125_CD ±_NN 1100_CD in_IN group_NN II_NNP (_( Table_NNP 3_LS )_) ._.
        Group_NNP II_NNP charges_NNS include_VBP the_DT additional_JJ fees_NNS for_IN the_DT
        nuclear_JJ medicine_NN brain_NN scan_VB (_( charges_NNS for_IN nuclear_JJ tracer_NN ,_,
        the_DT scan_VB itself_PRP and_CC professional_JJ fees_NNS for_IN interpretation_NN of_IN
        the_DT scan_VB )_) ,_, totaling_VBG nearly_RB $_$ 1500_CD ._. Therefore_RB ,_, the_DT true_JJ
        difference_NN in_IN ICU-related_NNP charges_NNS is_VBZ even_RB more_RBR
        significant_JJ ._.
        The_DT legal_JJ definition_NN of_IN brain_NN death_NN may_MD vary_VB between_IN
        different_JJ institutions_NNS and_CC states_NNS [_NN 11_CD ,_, 28_CD ]_NN ._. At_IN the_DT
        Hospital_NNP of_IN the_DT University_NNP of_IN Pennsylvania_NNP ,_, brain_NN death_NN
        confirmation_NN is_VBZ basically_RB defined_VBN by_IN the_DT three_CD protocols_NNS
        mentioned_VBN previously_RB ._. The_DT third_JJ method_NN ,_, that_IN of_IN using_VBG a_DT
        cerebral_JJ blood_NN flow_NN scan_VB (_( a_DT technique_NN which_WDT was_VBD previously_RB
        ordered_VBN rather_RB infrequently_RB at_IN our_PRP$ institution_NN )_) in_IN
        conjunction_NN with_IN only_RB one_CD brain_NN death_NN examination_NN ,_,
        dramatically_RB shortens_NNS brain_NN death_NN stay_NN ._. Therefore_RB ,_, we_PRP are_VBP
        currently_RB using_VBG this_DT method_NN in_IN order_NN to_TO minimize_VB brain_NN
        death_NN stay_NN and_CC maximize_VB organ_NN procurement_NN possibilities_NNS ;_:
        nuclear_JJ medicine_NN scans_VBZ can_MD be_VB performed_VBN quite_RB expeditiously_RB
        at_IN our_PRP$ institution_NN ._. In_IN most_JJS cases_NNS ,_, the_DT criteria_NNS for_IN brain_NN
        death_NN determination_NN by_IN nuclear_JJ scan_VB are_VBP clear_JJ cut_NN ,_, allowing_VBG
        a_DT decision_NN to_TO be_VB made_VBN without_IN equivocation_NN ._. The_DT brain_NN scan_VB
        technique_NN ,_, as_RB previously_RB described_VBD ,_, is_VBZ noninvasive_JJ ,_, usually_RB
        requiring_VBG only_RB a_DT venous_JJ access_NN line_NN to_TO adminster_NN the_DT radio_NN
        tracer_NN [_NN 34_CD ]_NN ._. There_EX are_VBP no_DT known_VBN side-effects_JJ of_IN such_JJ
        preparations_NNS and_CC therefore_RB organs_NNS of_IN interest_NN for_IN
        transplantation_NN ,_, such_JJ as_IN the_DT kidney_NN ,_, liver_NN ,_, heart_NN ,_, lungs_NNS
        and_CC pancreas_NN ,_, are_VBP not_RB affected_VBN by_IN performing_VBG this_DT type_NN of_IN
        examination_NN ._. The_DT results_NNS of_IN the_DT scan_VB are_VBP available_JJ within_IN
        30_CD min_NN of_IN radio_NN tracer_NN injection_NN and_CC the_DT technique_NN can_MD be_VB
        performed_VBN at_IN the_DT bedside_NN with_IN portable_JJ nuclear_JJ medicine_NN
        cameras_NNS ,_, although_IN these_DT are_VBP currently_RB unavailable_JJ at_IN our_PRP$
        institution_NN [_NN 27_CD ]_NN ._. While_IN cerebral_JJ arteriography_NN can_MD be_VB used_VBN
        for_IN the_DT same_JJ purposes_NNS ,_, it_PRP is_VBZ generally_RB more_RBR costly_JJ and_CC time_NN
        consuming_NN than_IN the_DT nuclear_JJ scan_VB [_NN 30_CD ,_, 32_CD ]_NN ._. Overall_RB ,_, the_DT
        nuclear_JJ scan_VB leads_VBZ to_TO a_DT decrease_NN in_IN associated_VBN charges_NNS and_CC
        is_VBZ safe_JJ ,_, fast_RB and_CC accurate_JJ [_NN 31_CD ]_NN ._. It_PRP has_VBZ become_VBN the_DT method_NN
        of_IN choice_NN to_TO determine_VB brain_NN death_NN in_IN our_PRP$ trauma_NN
        population_NN ._.
        An_DT additional_JJ potential_JJ benefit_NN of_IN rapid_JJ brain_NN death_NN
        determination_NN is_VBZ the_DT reduction_NN in_IN time_NN for_IN the_DT development_NN
        of_IN significant_JJ end_NN organ_NN dysfunction_NN ,_, thereby_RB increasing_VBG
        the_DT number_NN of_IN organs_NNS procured_JJ per_IN donor_NN ._. This_DT may_MD be_VB offset_VBN
        by_IN the_DT possibility_NN that_IN procurement_NN rates_NNS may_MD fall_VB if_IN
        families_NNS do_VBP not_RB have_VB enough_JJ time_NN to_TO grieve_NN ,_, and_CC may_MD
        therefore_RB be_VB more_RBR prone_JJ to_TO refuse_VB organ_NN donation_NN ._. Both_DT of_IN
        these_DT factors_NNS merit_VBP further_JJ investigation_NN ._.
        We_PRP specifically_RB examined_VBD institutional_JJ charges_NNS and_CC not_RB
        costs_VBZ associated_VBN with_IN the_DT care_NN of_IN the_DT potential_JJ organ_NN
        donor_NN ._. Charges_NNS are_VBP billed_VBN by_IN health_NN care_NN providers_NNS and_CC ,_,
        therefore_RB ,_, have_VBP the_DT advantage_NN of_IN being_VBG specific_JJ to_TO an_DT
        individual_JJ procedure_NN and_CC relatively_RB easy_JJ to_TO obtain_VB [_NN 35_CD ]_NN ._.
        Examining_NNP charges_NNS appears_VBZ to_TO be_VB somewhat_RB misleading_JJ because_IN
        for_IN any_DT one_CD given_VBN resource_NN they_PRP seem_VBP to_TO bear_VB little_JJ
        relationship_NN to_TO the_DT cost_NN ,_, and_CC are_VBP also_RB widely_RB variable_JJ
        between_IN institutions_NNS [_NN 36_CD ]_NN ._. However_RB ,_, charges_NNS are_VBP typically_RB
        related_VBN to_TO costs_NNS in_IN a_DT proportional_JJ sense_NN and_CC are_VBP therefore_RB
        useful_JJ in_IN measuring_VBG relative_JJ resource_NN consumption_NN [_NN 35_CD ]_NN ._. In_IN
        addition_NN ,_, because_IN this_DT study_NN addresses_VBZ issues_NNS pertinent_JJ to_TO
        health_NN care_NN utilizers_NNS (_( the_DT families_NNS of_IN potential_JJ organ_NN
        donors_NNS )_) ,_, as_RB well_RB as_IN to_TO health_NN care_NN providers_NNS ,_, we_PRP felt_VBD that_IN
        the_DT examination_NN of_IN charges_NNS rather_RB than_IN costs_NNS was_VBD
        relevant_JJ ._.
        This_DT study_NN has_VBZ several_JJ obvious_JJ shortcomings_NNS -_: its_PRP$ small_JJ
        sample_NN size_NN ,_, its_PRP$ retrospective_NN and_CC descriptive_JJ nature_NN ,_, and_CC
        the_DT fact_NN that_IN only_RB institutional_JJ charges_NNS (_( as_IN opposed_VBN to_TO
        cost_VB data_NNS )_) are_VBP examined_VBN ._. Also_RB ,_, we_PRP did_VBD not_RB attempt_VB to_TO
        identify_VB the_DT ultimate_JJ bearer_NN of_IN financial_JJ responsibility_NN
        for_IN these_DT charges_NNS ._. However_RB ,_, this_DT study_NN does_VBZ point_NN out_IN that_IN
        a_DT large_JJ cost_NN of_IN care_NN accumulates_NNS and_CC is_VBZ passed_VBN on_IN to_TO
        someone_NN (_( tax-payer_JJ ,_, insurance_NN company_NN or_CC family_NN )_) in_IN the_DT
        process_NN of_IN supporting_VBG organs_NNS for_IN transplantation_NN ._. At_IN the_DT
        institutional_JJ level_NN ,_, brain_NN death_NN protocols_NNS should_MD be_VB
        designed_VBN to_TO shorten_VB brain_NN death_NN stays_VBZ as_RB much_RB as_IN possible_JJ ._.
        At_IN our_PRP$ institution_NN ,_, the_DT nuclear_JJ medicine_NN cerebral_JJ blood_NN
        flow_NN scan_VB appears_VBZ to_TO fulfill_VB this_DT goal_NN successfully_RB ._. As_IN a_DT
        result_NN ,_, we_PRP have_VBP significantly_RB by_IN minimized_VBN charges_NNS
        associated_VBN with_IN the_DT determination_NN of_IN brain_NN death_NN ,_,
        regardless_RB of_IN who_WP ultimately_RB subsidizes_VBZ the_DT process_NN ._.
      
    
  
